Home » Stocks » MBIO

Mustang Bio, Inc. (MBIO)

Stock Price: $2.80 USD -0.10 (-3.45%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $2.81 +0.01 (0.36%) Jul 23, 7:59 PM
Market Cap 244.48M
Revenue (ttm) -50,000
Net Income (ttm) -63.12M
Shares Out 80.47M
EPS (ttm) -1.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $2.80
Previous Close $2.90
Change ($) -0.10
Change (%) -3.45%
Day's Open 2.90
Day's Range 2.75 - 2.92
Day's Volume 1,283,320
52-Week Range 2.42 - 5.22

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

WORCESTER, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell ...

1 month ago - GlobeNewsWire

Penny stocks to watch with upcoming event dates to keep in mind this week The post Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts appeared first on Penny Stocks to Buy, Picks, N...

Other stocks mentioned: CYTR, FBIO, MEIP, MTNB, ORPH
1 month ago - PennyStocks

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CLNY, IPW, VTGN, WDH
1 month ago - 24/7 Wall Street

Mustang Bio Inc (NASDAQ: MBIO) has updated interim data from the ongoing Phase 1/2 trial evaluating MB-106 for high-risk B-cell non-Hodgkin lymphomas (B-NHL) and chronic lymphocytic leukemia (CLL). The ...

1 month ago - Benzinga

Data presented at the European Hematology Association 2021 Virtual Congress show favorable safety profile and compelling clinical activity

1 month ago - GlobeNewsWire

These penny stocks are expecting to release key information this month. The post Biotech Penny Stocks To Watch For June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto...

Other stocks mentioned: APTO, FBIO, RGLS
1 month ago - PennyStocks

The biotech announced a clinical update and an analyst initiated coverage on the stock.

2 months ago - The Motley Fool

Penny stocks remain volatile but these analysts have a bright outlook on these The post 5 Penny Stocks To Watch Right Now That Analysts Are Bullish On appeared first on Penny Stocks to Buy, Picks, News ...

Other stocks mentioned: BNGO, EXPR, GTBP, MUX
2 months ago - PennyStocks

Mustang Bio Inc (NASDAQ: MBIO) and the City of Hope, an independent cancer research and treatment center, have dosed the first patient in Phase 1 trial evaluating MB-101 in patients with leptomeningeal ...

2 months ago - Benzinga

First dose occurred in trial underway at City of Hope to evaluate safety and feasibility of administering therapy in patients with brain tumors such as glioblastoma, ependymoma or medulloblastoma First ...

2 months ago - GlobeNewsWire

WORCESTER, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell a...

2 months ago - GlobeNewsWire

Fred Hutchinson Cancer Research Center to present updated interim data from ongoing MB-106 Phase 1/2 clinical trial Fred Hutchinson Cancer Research Center to present updated interim data from ongoing MB...

2 months ago - GlobeNewsWire

The Phase 1/2 multicenter study to assess the safety, tolerability and efficacy of MB-106 in patients with relapsed or refractory CD20+ B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia is ex...

2 months ago - GlobeNewsWire

NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gen...

4 months ago - GlobeNewsWire

WORCESTER, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell ...

4 months ago - GlobeNewsWire

Many penny stocks are destined to fail, but these seven penny stocks may succeed. Wall Street has buy recommedations on them.

Other stocks mentioned: ALNA, ALRN, MCHX, MDWD, OBSV, RWLK
5 months ago - InvestorPlace

Mustang Bio (NASDAQ: MBIO) shares are trading higher after the company announced the FDA has lifted the clinical hold for its pivotal phase 2 MB-107 clinical trial. The company plans to enroll the first...

Other stocks mentioned: PHAT, BNGO, IMVT
5 months ago - Benzinga

FDA removes clinical hold for pivotal Phase 2 MB-107 clinical trial

5 months ago - GlobeNewsWire

Penny stocks are cheap for a reason, as there are obvious flaws. However, with those flows comes opportunity.

Other stocks mentioned: CAIXY, CLVS, DHT, OPK, RNWK, RYCEY
6 months ago - InvestorPlace

WORCESTER, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell ...

6 months ago - GlobeNewsWire

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can b...

Other stocks mentioned: FL, GME, NTAP, ARVN, BCAB, COUP, EOSE ...
6 months ago - Benzinga

Data presented at the 62 nd American Society of Hematology (ASH) Annual Meeting show extremely favorable safety profile and clinical activity

7 months ago - GlobeNewsWire

Investors need to pay close attention to Mustang Bio (MBIO) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

Call to be held Wednesday, December 9, 2020, at 1:00 p.m. EST Call to be held Wednesday, December 9, 2020, at 1:00 p.m. EST

7 months ago - GlobeNewsWire

WORCESTER, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell ...

8 months ago - GlobeNewsWire

WORCESTER, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell ...

8 months ago - GlobeNewsWire

WORCESTER, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell ...

8 months ago - GlobeNewsWire

Biotech stocks are always going to be here, in good times and bad. Let's look at a few that are worth considering on the long side.

Other stocks mentioned: ABBV, AMGN, BLUE, BMY, REGN, VRTX
8 months ago - InvestorPlace

Data presented by City of Hope at 27th Annual Prostate Cancer Foundation Scientific Retreat Data presented by City of Hope at 27th Annual Prostate Cancer Foundation Scientific Retreat

8 months ago - GlobeNewsWire

WORCESTER, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell ...

9 months ago - GlobeNewsWire

Mustang to leverage LentiBOOST™ for the development of MB-207 lentiviral gene therapy Mustang to leverage LentiBOOST™ for the development of MB-207 lentiviral gene therapy

9 months ago - GlobeNewsWire

WORCESTER, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell ...

9 months ago - GlobeNewsWire

WORCESTER, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in ce...

10 months ago - GlobeNewsWire

Investors need to pay close attention to Mustang Bio (MBIO) stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

WORCESTER, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cel...

10 months ago - GlobeNewsWire

Mustang Bio: Slow, Steady Progress Towards Multiple Gene And CAR-T Therapy Goals

10 months ago - Seeking Alpha

Investors need to pay close attention to Mustang Bio (MBIO) stock based on the movements in the options market lately.

11 months ago - Zacks Investment Research

WORCESTER, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cel...

11 months ago - GlobeNewsWire

WORCESTER, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cel...

11 months ago - GlobeNewsWire

Mustang Bio (MBIO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

Mustang Bio, Inc. (NASDAQ: MBIO) shares are trading lower after the company announced a common stock offering of 10.769 million shares at $3.25 per share.

1 year ago - Benzinga

Mustang Bio (MBIO) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

WORCESTER, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cel...

1 year ago - GlobeNewsWire

Mustang (MBIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

NEW YORK, April 20, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and g...

1 year ago - GlobeNewsWire

The subject achieved a complete response The subject achieved a complete response

1 year ago - GlobeNewsWire

NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and ge...

1 year ago - GlobeNewsWire

Mustang Bio, Inc. (MBIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

1 year ago - Zacks Investment Research

The American Society of Hematology's 61st annual meeting is underway in Orlando, Florida.

Other stocks mentioned: DTIL, FTSV, RHHBY, TGTX
1 year ago - Benzinga

As investors consider the current market conditions today, many should be prepared for what is coming and how looking beyond the benchmark through customized ETF strategies may help diversify risks ahead.

Other stocks mentioned: DIAL, RECS, REVS
1 year ago - ETF Trends

About MBIO

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare g... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
MBIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Mustang Bio stock is "Strong Buy." The 12-month stock price forecast is 10.40, which is an increase of 271.43% from the latest price.

Price Target
$10.40
(271.43% upside)
Analyst Consensus: Strong Buy